AbbVie Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Interest-Expense" stands at 2.81 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
AbbVie Inc's third quarter result of 0.667 Billion USD for the item "Interest Expense" represents a decrease of -9.86 percent compared to it's second quarter result.
Also, AbbVie Inc's third quarter result of 0.667 Billion USD for the item "Interest Expense" represents a decrease of -7.36 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), AbbVie Inc's third quarter result of 2.81 Billion USD for the item "Interest Expense" represents a decrease of -1.85 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 5.21 percent compared to the value the year prior.
The 1 year change in percent is 5.21.
The 3 year change in percent is 25.18.
The 5 year change in percent is 17.83.
The 10 year change in percent is 332.15.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Interest Expense | 905,699,262,464.00 |
![]() | Johnson & Johnson - Interest Expense | 486,508,953,600.00 |
![]() | Roche Holding AG - Interest Expense | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Interest Expense | 280,205,508,085.11 |
![]() | Novartis AG - Interest Expense | 255,096,620,580.91 |